Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
facilities
Pharma
Boehringer Ingelheim divests biologics CDMO unit in China
Blood products developer Raas will pay up to around $3 million to secure a 100% stake in a Boehringer Ingelheim biologics CDMO unit in China.
Fraiser Kansteiner
Sep 24, 2026 11:38am
Alembic site hit with warning letter on patient consent concerns
Jul 21, 2026 11:40am
FDA unveils 1-day assessment pilot to complement inspections
May 6, 2026 3:08pm
FDA clarifies Form 483 expectations after production inspections
May 1, 2026 10:52am
Astellas manufacturing chief talks strategy 1 year into role
Apr 15, 2026 10:35am
Fierce Biotech
AstraZeneca vows $15B China investment to boost R&D capabilities
Jan 29, 2026 5:50am
